Cellular signal-specific peptide substrate is essential for the gene delivery system responding to cellular signals

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6082-6086

  Kang, Jeong Hun ^a   Toita, Riki ^a   Tomiyama, Tetsuro ^a   Oishi, Jun ^a   Asai, Daisuke ^b   Mori, Takeshi ^a   Niidome, Takuro ^a   Katayama, Yoshiki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cationic polymer; Diagnosis; Gene therapy; Intracellular signal; Peptide substrate

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; LEUCYLARGINYLVALYLGLUTAMINYLASPARAGINYLALANYLLEUCYLARGINYLARGINYL ARGINYLARGININE; LEUCYLARGINYLVALYLGLUTAMINYLASPARAGINYLSERYLLEUCYLARGINYLARGINYL ARGINYLARGININE; POLYMER; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; SERINE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MELANOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; ISOENZYMES; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 71749091872     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.034     Document Type: Article

References (26)

1. Yamanishi D.T., and Meyskens Jr. F.L. Crit. Rev. Oncogene 5 (1994) 429
2. Hug H. Biochem. J. 291 (1993) 329
3. Newton A.C. Curr. Opin. Cell Biol. 9 (1997) 161
4. Mackay H.J., and Twelves C.J. Endocrine Relat. Cancer 10 (2003) 389
5. Kim Y.P., Oh E., Oh Y.H., Moon D.W., Lee T.G., and Kim H.S. Angew. Chem., Int. Ed. Engl. 46 (2007) 6816
6. Oishi J., Asami Y., Kang J.H., Tanabe M., Niidome T., and Katayama Y. Chembiochem 8 (2007) 875
7. Lejeune F.J., Rimoldi D., and Speiser D. Exp. Rev. Anti-cancer Ther. 7 (2007) 701
8. Oishi J., Kawamura K., Kang J.H., Kodama K., Sonoda T., Murata M., Niidome T., and Katayama Y. J. Controlled Release 110 (2006) 431
9. Oishi J., Ijuin M., Sonoda T., Kang J.H., Kawamura K., Mori T., Niidome T., and Katayama Y. Bioorg. Med. Chem. Lett. 16 (2006) 5740
10. Kawamura K., Oishi J., Kang J.H., Kodama K., Sonoda T., Murata M., Niidome T., and Katayama Y. Biomacromolecules 6 (2005) 908
11. Asai D., Tsuchiya A., Kang J.H., Kawamura K., Oishi J., Mori T., Niidome T., Shoji Y., Nakashima H., and Katayama Y. J. Gene Med. 11 (2009) 624
12. Kang J.H., Asai D., Kim J.H., Mori T., Toita R., Tomiyama T., Asami Y., Oishi J., Sato Y.T., Niidome T., Jun B., Nakashima H., and Katayama Y. J. Am. Chem. Soc. 130 (2008) 14906
13. Asai D., Kang J.H., Toita R., Tsuchiya A., Niidome T., Nakashima H., and Katayama Y. Nanoscale Res. Lett. 4 (2009) 229
14. Tomiyama T., Kang J.H., Toita R., Niidome T., and Katayama Y. Cancer Sci. 100 (2009) 1532
15. Kang J.H., Asai D., Yamada S., Toita R., Oishi J., Mori T., Niidome T., and Katayama Y. Proteomics 8 (2008) 2006
16. Kang J.H., Katayama Y., Han A., Shigaki S., Oishi J., Kawamura K., Toita R., Han X.H., Mori T., and Niidome T. J. Am. Soc. Mass Spectrom. 18 (2007) 106
17. Taniguchi H., Manenti S., Suzuki M., and Titani K. J. Biol. Chem. 269 (1994) 18299
18. Garnett M.C. Crit. Rev. Ther. Drug Carr. Syst. 16 (1999) 147
19. Pichon C., Goncalves C., and Midoux P. Adv. Drug Delivery Rev. 53 (2001) 75
20. Jun Y.J., Kim J.H., Choi S.J., Lee H.J., Jun M.J., and Sohn Y.S. Bioorg. Med. Chem. Lett. 11 (2007) 2975
21. Goekjian P.G., and Jirousek M.R. Exp. Opin. Invest. Drugs 10 (2001) 2117
22. Beauparlant P., and Shore G.C. Curr. Opin. Drug Discovery Dev. 6 (2003) 179
23. Martin P.M., and Hussaini I. Exp. Opin. Ther. Targets 9 (2005) 299
24. Lahn M., and Sundell L. Melanoma Res. 14 (2004) 85
25. Jaken S. Curr. Opin. Cell Biol. 2 (1990) 192
26. Oka M., and Kikkawa U. Cancer Metastasis Rev. 24 (2005) 287